These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 26364602)

  • 41. YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers.
    Galli GG; Carrara M; Yuan WC; Valdes-Quezada C; Gurung B; Pepe-Mooney B; Zhang T; Geeven G; Gray NS; de Laat W; Calogero RA; Camargo FD
    Mol Cell; 2015 Oct; 60(2):328-37. PubMed ID: 26439301
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ci antagonizes Hippo signaling in the somatic cells of the ovary to drive germline stem cell differentiation.
    Li C; Kan L; Chen Y; Zheng X; Li W; Zhang W; Cao L; Lin X; Ji S; Huang S; Zhang G; Liu X; Tao Y; Wu S; Chen D
    Cell Res; 2015 Oct; 25(10):1152-70. PubMed ID: 26403189
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TAZ Protein Accumulation Is Negatively Regulated by YAP Abundance in Mammalian Cells.
    Finch-Edmondson ML; Strauss RP; Passman AM; Sudol M; Yeoh GC; Callus BA
    J Biol Chem; 2015 Nov; 290(46):27928-38. PubMed ID: 26432639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PAR1 participates in the ability of multidrug resistance and tumorigenesis by controlling Hippo-YAP pathway.
    Fujimoto D; Ueda Y; Hirono Y; Goi T; Yamaguchi A
    Oncotarget; 2015 Oct; 6(33):34788-99. PubMed ID: 26431277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. An Imbalance in TAZ and YAP Expression in Hepatocellular Carcinoma Confers Cancer Stem Cell-like Behaviors Contributing to Disease Progression.
    Hayashi H; Higashi T; Yokoyama N; Kaida T; Sakamoto K; Fukushima Y; Ishimoto T; Kuroki H; Nitta H; Hashimoto D; Chikamoto A; Oki E; Beppu T; Baba H
    Cancer Res; 2015 Nov; 75(22):4985-97. PubMed ID: 26420216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. FOXC2 and fluid shear stress stabilize postnatal lymphatic vasculature.
    Sabine A; Bovay E; Demir CS; Kimura W; Jaquet M; Agalarov Y; Zangger N; Scallan JP; Graber W; Gulpinar E; Kwak BR; Mäkinen T; Martinez-Corral I; Ortega S; Delorenzi M; Kiefer F; Davis MJ; Djonov V; Miura N; Petrova TV
    J Clin Invest; 2015 Oct; 125(10):3861-77. PubMed ID: 26389677
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Signaling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge.
    Piersma B; Bank RA; Boersema M
    Front Med (Lausanne); 2015; 2():59. PubMed ID: 26389119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer.
    Xue X; Yang YA; Zhang A; Fong KW; Kim J; Song B; Li S; Zhao JC; Yu J
    Oncogene; 2016 May; 35(21):2746-55. PubMed ID: 26364613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Verteporfin, a suppressor of YAP-TEAD complex, presents promising antitumor properties on ovarian cancer.
    Feng J; Gou J; Jia J; Yi T; Cui T; Li Z
    Onco Targets Ther; 2016; 9():5371-81. PubMed ID: 27621651
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Localization of Hippo signalling complexes and Warts activation in vivo.
    Sun S; Reddy BV; Irvine KD
    Nat Commun; 2015 Sep; 6():8402. PubMed ID: 26420589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer.
    Romero-Pérez L; Garcia-Sanz P; Mota A; Leskelä S; Hergueta-Redondo M; Díaz-Martín J; López-García MA; Castilla MA; Martínez-Ramírez A; Soslow RA; Matias-Guiu X; Moreno-Bueno G; Palacios J
    Mod Pathol; 2015 Nov; 28(11):1492-503. PubMed ID: 26381823
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of reproductive hormones in epithelial ovarian carcinogenesis.
    Gharwan H; Bunch KP; Annunziata CM
    Endocr Relat Cancer; 2015 Dec; 22(6):R339-63. PubMed ID: 26373571
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scaling the Drosophila Wing: TOR-Dependent Target Gene Access by the Hippo Pathway Transducer Yorkie.
    Parker J; Struhl G
    PLoS Biol; 2015 Oct; 13(10):e1002274. PubMed ID: 26474042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins.
    Wang W; Li N; Li X; Tran MK; Han X; Chen J
    Cell Rep; 2015 Oct; 13(3):524-532. PubMed ID: 26456820
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Control of Proliferation and Cancer Growth by the Hippo Signaling Pathway.
    Ehmer U; Sage J
    Mol Cancer Res; 2016 Feb; 14(2):127-40. PubMed ID: 26432795
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Exploiting Expression of Hippo Effector, Yap, for Expansion of Functional Islet Mass.
    George NM; Boerner BP; Mir SU; Guinn Z; Sarvetnick NE
    Mol Endocrinol; 2015 Nov; 29(11):1594-607. PubMed ID: 26378466
    [TBL] [Abstract][Full Text] [Related]  

  • 57. MST kinases in development and disease.
    Thompson BJ; Sahai E
    J Cell Biol; 2015 Sep; 210(6):871-82. PubMed ID: 26370497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. MDP, a database linking drug response data to genomic information, identifies dasatinib and statins as a combinatorial strategy to inhibit YAP/TAZ in cancer cells.
    Taccioli C; Sorrentino G; Zannini A; Caroli J; Beneventano D; Anderlucci L; Lolli M; Bicciato S; Del Sal G
    Oncotarget; 2015 Nov; 6(36):38854-65. PubMed ID: 26513174
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stressing out the Hippo/YAP signaling pathway: toward a new role in Schwann cells.
    Melfi S; Colciago A; Giannotti G; Bonalume V; Caffino L; Fumagalli F; Magnaghi V
    Cell Death Dis; 2015 Oct; 6(10):e1915. PubMed ID: 26469964
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.